Identification of Multiple Cryptococcal Fungicidal Drug Targets by Combined Gene Dosing and Drug Affinity Responsive

Yoon-Dong Park1, Wei Sun2, Antonio Salas1

  • 1Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Mbio
|August 4, 2016
PubMed
Abstract

Insights

Researchers identified a common drug target site in dehydrogenases for the fungicidal drug bithionol. This discovery offers a new strategy for developing effective antifungal therapies against Cryptococcus neoformans meningitis.

Area of Science:

  • Mycology
  • Drug Discovery
  • Biochemistry

Background:

  • Cryptococcus neoformans causes nearly half a million deaths globally from meningitis, particularly in immunocompromised individuals.
  • Current fungistatic drugs like fluconazole have limited efficacy, while the potent fungicidal drug amphotericin B presents toxicity and administration challenges.
  • There is a critical need for novel, effective, and safer antifungal therapies targeting this neglected fungal pathogen.

Purpose of the Study:

  • To identify novel fungicidal drug targets for Cryptococcus neoformans.
  • To elucidate the mechanism of action of the potent fungicidal agent, bithionol.
  • To explore a new multitarget approach for antifungal drug development.

Main Methods:

  • Utilized a combined gene dosing and drug affinity responsive target stability (GD-DARTS) screen.
  • Employed protein modeling to analyze drug-target interactions.
  • Investigated the fungicidal activity of bithionol against Cryptococcus neoformans.

Main Results:

  • Identified a common drug binding site for bithionol across multiple NAD-dependent dehydrogenase enzymes.
  • Demonstrated that bithionol simultaneously inhibits and kills the fungus by targeting these dehydrogenases.
  • Highlighted the role of dehydrogenases in fungal nutrient homeostasis.

Conclusions:

  • The study successfully identified a conserved multitarget site for antifungal drug development.
  • The combined genetic and proteomic approach provides a powerful platform for discovering new antifungal drug targets.
  • Bithionol's mechanism offers a promising avenue for developing next-generation fungicidal therapies against cryptococcosis.